KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc.

KT-621（STAT6）和KT-294（TYK2）有可能通过口服小分子谱提供类似生物制剂的活性KT-621（STAT6）预计将在2024年下半年开始第一阶段，KT-294（TYK2）预计将在2025年上半年开始第一阶段，这两个阶段的数据均来自2025年3月8日的马萨诸塞州沃特敦（WATERTOWN），2024年（Global NEWSWIRE）-Kymera Therapeutics，Inc。

(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California.

（纳斯达克：KYMR），一家临床阶段的生物制药公司，利用靶向蛋白质降解（TPD）开发了一类新的小分子药物，今天宣布其临床前数据证明了其有效和选择性的STAT6（KT-621）和TYK2（KT-294）异双功能降解剂的治疗潜力正在加利福尼亚州圣地亚哥举行的美国皮肤病学会年会上的海报会议上展出。

Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting.

Kymera的口服STAT6和TYK2降解剂有可能解决多种免疫介导的疾病，并克服现有技术和药物的局限性。今天的海报展示标志着STAT6靶向药物和TYK2降解剂的数据首次在大型医学会议上共享。

Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025. “Our differentiated strategy to targeted protein degradation has resulted in an industry-leading immunology pipeline of oral degrader medicines, each with the potential to treat multiple complex immuno-inflammatory diseases.

根据迄今为止产生的结果，Kymera计划分别于2024年下半年和2025年上半年启动KT-621和KT-294的第一阶段测试。预计2025年将报告第一阶段试验的数据。“我们针对蛋白质降解的差异化策略已经产生了业界领先的口服降解药物免疫学流水线，每种药物都有可能治疗多种复杂的免疫炎症疾病。

Our preclinical findings demonstrate the potential advantage of using oral degraders over other technologies to effectively drug critical signaling nodes driving inflammation in a variety of d.

我们的临床前研究结果表明，与其他技术相比，使用口服降解剂可以有效地治疗驱动各种d中炎症的关键信号节点。